These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30758417)

  • 1. The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.
    Li JJ; Zhang P; Fan B; Guo XL; Zheng ZS
    Rev Assoc Med Bras (1992); 2019 Jan; 65(1):33-37. PubMed ID: 30758417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Tian F; Zheng Z; Zhang D; He S; Shen J
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.
    Lin X; Zhang Z; Chen JM; Xu YY; Ye HR; Cui J; Fang Y; Jin Y; Zhu DR; Yuan L
    Genet Mol Res; 2015 Apr; 14(2):2940-6. PubMed ID: 25966055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic effect of saxagliptin in rat models of nonalcoholic fatty liver and type 2 diabetes].
    Liu Y; Zhang Z; Chen R; Sun J; Chen H
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jun; 34(6):862-8. PubMed ID: 24968846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid.
    Li YL; Xie H; Musha H; Xing Y; Mei CX; Wang HJ; Wulasihan M
    Cell Biochem Biophys; 2015 Jul; 72(3):643-7. PubMed ID: 27352181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
    Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
    [No Abstract]   [Full Text] [Related]  

  • 9. [Electroacupuncture combined with lifestyle control on obese nonalcoholic fatty liver disease: a randomized controlled trial].
    Dong C; Zhang CR; Xue BY; Miu WF; Fang NY; Li K; Ou ZJ; Xu YQ
    Zhongguo Zhen Jiu; 2020 Feb; 40(2):129-34. PubMed ID: 32100496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.
    Zhang LY; Jin YJ; Jin QS; Lin LY; Zhang DD; Kong LL
    Gene; 2013 Oct; 529(2):340-4. PubMed ID: 23954219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
    Chen Y; Wang XJ; Jin HL; Jin L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus.
    Chen K; Zhuo T; Wang J; Mei Q
    Metab Syndr Relat Disord; 2018 Sep; 16(7):336-341. PubMed ID: 29912623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential influence of miR-192 on the efficacy of saxagliptin treatment in T2DM complicated with non-alcoholic fatty liver disease.
    An P; Peng Q; Guo T; Xing PC; Zhao LD; Zhou MJ
    J Biol Regul Homeost Agents; 2020 Jul-Aug,; 34(4):1411-1415. PubMed ID: 32829627
    [No Abstract]   [Full Text] [Related]  

  • 16. [Zuogui Jiangtang Qinggan Formula improves glucolipid metabolism in type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease by regulating FoxO1/MTP/APOB signaling pathway].
    Xiang YX; Huang YL; Zhou M; Zou JJ; Liu X; Liu ZY; Xiao F; Yu R; Xiang Q
    Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(16):4438-4445. PubMed ID: 37802870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus.
    Zhang Z; Wang J; Wang H
    Exp Ther Med; 2018 Mar; 15(3):2936-2940. PubMed ID: 29456698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance is independently associated with liver aminotransferases in diabetic patients without ultrasound signs of nonalcoholic fatty liver disease.
    Esteghamati A; Noshad S; Khalilzadeh O; Khalili M; Zandieh A; Nakhjavani M
    Metab Syndr Relat Disord; 2011 Apr; 9(2):111-7. PubMed ID: 21091060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.
    Cahn A; Raz I; Mosenzon O; Leibowitz G; Yanuv I; Rozenberg A; Iqbal N; Hirshberg B; Sjostrand M; Stahre C; Im K; Kanevsky E; Scirica BM; Bhatt DL; Braunwald E
    Diabetes Care; 2016 Aug; 39(8):1329-37. PubMed ID: 27222508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Change and correlated factors of fasting level of the plasma endotoxin in subjects with different glucose tolerances and body mass indices].
    Liu YH; Zhao TY; Hou LQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):769-73, 778. PubMed ID: 24325109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.